Tissue Regenix Group PLC (AIM:TRX) says trading remains on track as it continues executing its 4S strategy and targets further growth in 2025. The company is still reviewing strategic options, which has delayed its final results for 2024. A new results date and an update on the review will be announced in due course.
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com